Van Lümig, P P M <br/><br/>
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.  [electronic resource] 

 -  The British journal of dermatology  Oct 2010 
 - 838-46 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2133.2010.09950.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Dermatologic Agents--adverse effects<br/>Etanercept<br/>Female<br/>Humans<br/>Immunoglobulin G--adverse effects<br/>Immunosuppressive Agents--adverse effects<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Psoriasis--drug therapy<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Severity of Illness Index<br/>Treatment Failure<br/>Treatment Outcome